BRCA mutation frequency and penetrance: New data, old debate

Journal of the National Cancer Institute

Volumn 98, Issue 23, 2006, Pages 1675-1677

  Offit, Kenneth ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA;

BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER SURGERY; CHEMOPROPHYLAXIS; DNA DETERMINATION; EDITORIAL; ETHNIC DIFFERENCE; FAMILY HISTORY; GENE FREQUENCY; GENE MUTATION; HETEROZYGOTE; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; KIDNEY CANCER; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DOCUMENTATION; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PRIORITY JOURNAL; RISK REDUCTION; SELF REPORT; STOMACH CANCER; TESTIS CANCER;

BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENES, BRCA1; GENES, BRCA2; HUMANS; MALE; MUTATION; RISK ASSESSMENT;

EID: 33845659623     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj500     Document Type: Editorial

References (39)

1. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2002;94:1221-6.
2. Amos CR. Re: On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2003;95:74-5.
3. Risch H, Narod S. Re: On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2003;95:73-4.
4. Pharoah PP, Antoniou A, Hopper J, Easton D. Re: On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2003;95:75-6.
5. Whittemore AS, Gong G. Re: On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2003;95:76-7.
6. Burke W, Austin MA. Re: On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2003;95: 78-9.
7. Easton DF, Hopper JL, Thomas DC, Antoniou A, Pharoah PDP, Whittemore AS. Re: Breast cancer risks for BRCA1/2 carriers. Science 2004;306: 2187-8.
8. Wacholder S, Struewing JP, Hartge P, Greene MH, Tucker MA. Re: Breast cancer risks for BRCA1/2 carriers. Science 2004;306:2188.
9. King MC; New York Breast Cancer Study Group. Re: Breast cancer risks for BRCA1/2 carriers. Science 2004;306:2188-91.
10. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005;23:276-92.
11. Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 2005;23:1656-63.
12. Risch HA, McLaughlin JR, Cole DEC, Rosen B, Bradley L, Fan I, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694-706.
13. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
14. Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410-9.
15. Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. Breast Cancer Linkage Consortium. J Natl Cancer Inst 2002;94:1358-65.
16. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91:1310-6.
17. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365-72.
18. Wacholder S, Hartge P, Struewing JP, Pee D, McAdams M, Brody L, et al. The kin-cohort study for estimating penetrance. Am J Epidemiol 1998;148:623-30.
19. Hopper JL, Bishop DT, Easton DF. Population-based family studies in genetic epidemiology. Lancet 2005;366:1397-406.
20. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-5.
21. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-71.
22. Marroni F, Aretini P, D'Andrea E, Caligo MA, Cortesi L, Viel A, et al. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. Eur J Hum Genet 2004;12:899-906.
23. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60:496-504.
24. Bonadona V, Sinilnikova OM, Chopin S, Antoniou AC, Mignotte H, Mathevet P, et al. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: Results from a prospective population-based study in France. Genes Chromosomes Cancer 2005;43:404-13.
25. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer 2000;83:1301-8.
26. Lalloo F, Varley J, Ellis D, Moran A, O'Dair L, Pharoah P, et al. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 2003;361:1101-2.
27. King MC, Marks JH, Mandell JB. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6.
28. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 2003;72: 1117-30.
29. Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999;91:1241-7.
30. Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2001;10:467-73.
31. Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006;24:863-71.
32. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
33. Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999;8:741-7.
34. Easton DF, Steele L, Fields P, Ormiston W, Averil D, Daly PA, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997;61:120-8.
35. Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998;352:1337-9.
36. Offit K, Thom P. Cancer risks in BRCA1 and BRCA2 mutation carriers. In: Rebbeck T, Isaacs C, editors. Hereditary breast cancer. Informa. In press 2007.
37. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-15.
38. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:159-64.
39. Robson ME, Offit K. Breast MRI for women with hereditary cancer risk. JAMA 2004;292:1368-70.